Biogen to acquire Apellis Pharmaceuticals for approximately $5.6bn
MLex Summary: Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc. for $41 per share, a deal worth approximately $5.6 billion, the companies announced. The transaction, which is expected to close...To view the full article, register now.
Already a subscriber? Click here to view full article